NCT04797104View on ClinicalTrials.gov

Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction

PHASE3CompletedINTERVENTIONAL
Enrollment

478

Participants

Timeline

Start Date

April 22, 2021

Primary Completion Date

July 30, 2023

Study Completion Date

December 5, 2023

Conditions
Heterozygous Familial Hypercholesterolemia
Interventions
DRUG

lerodalcibep

300 mg Q4W

Trial Locations (7)

2193

Carbohydrate and Lipid Metabolism Research Unit, Johannesburg

7925

Division of Lipidology, Department of Medicine University of Cape Town, Cape Town

12000

Department of Medicine, Hadassah University Hospital, Jerusalem

35040

Ege University Medical School, Izmir

45227

Metabolic & Atherosclerosis Research Center (MARC), Cincinnati

49100

Rabin Medical Center, Beilinson Hospital,, Petah Tikva

0586

Lipid Clinic, Oslo University Hospital, Oslo

Sponsors

Collaborators (1)

Medpace, Inc.
All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

LIB Therapeutics LLC

INDUSTRY

NCT04797104 - Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction | Biotech Hunter | Biotech Hunter